Ophthalmology · Wet Age-Related Macular Degeneration

Recognizing Symptoms and Understanding Progression

At a Glance

Wet AMD can cause wavy lines, a blurred or dark central spot, and slower reading, yet one eye may hide changes in the other. Test each eye as directed and contact a retina clinic promptly about new symptoms because untreated disease can permanently damage vision.

The symptoms of wet age-related macular degeneration (wet AMD) can appear suddenly, but they often “hide” in plain sight. Because your brain is excellent at compensating for vision loss, you may not notice a problem until the disease has progressed ^[1]. Understanding the specific ways your vision can change—and why you might not notice it at first—is the first step in protecting your sight.

The Daily Impact of Vision Distortion

Wet AMD primarily affects your macula, the part of the eye that handles “high-definition” tasks ^[2]. When fluid leaks into this area, it physically displaces the light-sensing cells, leading to several distinct symptoms:

Metamorphopsia: This is a hallmark of wet AMD where straight lines appear wavy, bent, or distorted ^[3]. A door frame might look curved, or the lines on a page of text may seem to “dip” ^[4].
Central Scotoma: You may notice a blurred, gray, or dark “blind spot” in the very center of your vision ^[5]. While your peripheral vision is often relatively preserved, this central spot can make it impossible to recognize faces or read a watch, and function can still be impaired.
Loss of Reading Speed: Even before a blind spot appears, you may find that reading becomes slower and more fatiguing ^[3]. Words may seem to jump or disappear as you move your eyes across a line.

Why One Eye Can “Hide” the Other

It is common for patients to be surprised by a diagnosis in one eye when they haven’t noticed any symptoms. This happens because of binocular compensation: when both eyes are open, your “good” eye fills in the gaps for the “bad” eye ^[6]. Your brain stitches together a single, clear image, which can sometimes mask the distortion or blind spots present in the affected eye ^[1].

This “masking” effect is why doctors insist you test your eyes individually according to the monitoring schedule and method recommended by your clinician. If you only check your vision with both eyes open, you may miss the critical window where treatment is most effective ^[7].

The “Silent” Progression

Untreated wet AMD can lead to rapid and permanent vision loss. While the speed of progression varies, research shows that:

Permanent Damage: Without treatment, the risk of developing macular atrophy (the “wasting away” of retinal tissue) increases ^[8].
Emergency Situations: A major complication called a submacular hemorrhage (a large bleed under the retina) is a visual emergency that requires prompt assessment, as untreated activity or a large hemorrhage can cause rapid, sometimes permanent damage ^[9].
Scarring: Over time, untreated fluid leads to fibrosis (scarring), which creates a permanent blind spot that injections cannot fix ^[2]^[10].

PCV: A Specialized Variant

Some patients are diagnosed with a specific subtype of wet AMD called Polypoidal Choroidal Vasculopathy (PCV) ^[11].

What it is: In PCV, the abnormal blood vessels develop tiny, aneurysm-like bulges called “polyps” ^[12]. These polyps are more likely to cause sudden, large bleeds or significant swelling ^[11].
Who gets it: PCV is more common in many East Asian populations, compared to White populations, though it occurs in all demographics ^[13]^[14].
Treatment differences: While standard injections (anti-VEGF) work for PCV, some patients may also benefit from a specialized laser treatment called Photodynamic Therapy (PDT) to help close the polyps ^[15]^[16].

The Limits of the Amsler Grid

For decades, patients were told to use the Amsler Grid (a grid of black lines on a white background) to monitor their vision at home. However, modern research shows that the grid is an imperfect tool:

Low Sensitivity: Studies suggest the Amsler grid only catches a fraction of new cases of wet AMD compared to clinical scans ^[17]. This means your grid could look “normal” even while a leak is developing.
Better Alternatives: Clinical scans like OCT (Optical Coherence Tomography) are significantly more accurate ^[7].

While you should still use your home tools as directed, they are not a replacement for your scheduled appointments with a retina specialist ^[18]. Emphasize that any new change warrants contact with your clinic, even if the Amsler grid looks normal.

Common questions in this guide

What are the first symptoms of wet AMD?

Wet AMD may make straight lines look wavy, bent, or broken and can cause a blurred, gray, or dark spot in the center of your vision. Reading may become slower or more tiring, even before a clear blind spot appears.

Why might I not notice wet AMD in one eye?

Your stronger eye and brain can compensate for changes in the affected eye when both eyes are open. Testing each eye separately, as your clinician recommends, can reveal distortion or blind spots that binocular vision hides.

Can a normal Amsler grid rule out wet AMD activity?

No. The Amsler grid can miss some new changes, so a normal result does not replace scheduled appointments or clinical scans. Contact your eye clinic about any new vision change even if the grid looks normal.

How urgent is a new central blind spot or possible bleeding?

New central vision changes can signal active wet AMD and should be reported to your eye clinic promptly. A large bleed under the retina, called a submacular hemorrhage, is a visual emergency because it can cause rapid and sometimes permanent damage.

What is PCV, and might I need photodynamic therapy?

Polypoidal choroidal vasculopathy, or PCV, is a subtype of wet AMD in which abnormal blood vessels form small bulges that can bleed or cause swelling. Anti-VEGF injections can help, and some people may also benefit from photodynamic therapy to close the polyps; your retina specialist can advise you.

How should I monitor my vision at home?

Test each eye separately according to the schedule and method recommended by your clinician. Watch for wavy lines, a new central blank or smudged area, slower reading, or other changes, and tell your clinic promptly; home tools do not replace professional monitoring.

Get notified when new evidence is published on wet macular degeneration.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
Improved Structure and Function in Early-Detected Second-Eye Neovascular Age-Related Macular Degeneration: FASBAT/Early Detection of Neovascular Age-Related Macular Degeneration Report 1.
Gale RP, Airody A, Sivaprasad S, et al.
Ophthalmology. Retina 2024; (8(6)):545-552 doi:10.1016/j.oret.2023.12.012.
PMID: 38171416
2
Novel approach to antiangiogenic factors in age-related macular degeneration therapy.
Samelska K, Kupis M, Izdebska J, et al.
Central-European journal of immunology 2022; (47(1)):117-123 doi:10.5114/ceji.2022.113103.
PMID: 35600160
3
Clinical Update on Metamorphopsia: Epidemiology, Diagnosis and Imaging.
Hanumunthadu D, Lescrauwaet B, Jaffe M, et al.
Current eye research 2021; (46(12)):1777-1791 doi:10.1080/02713683.2021.1912779.
PMID: 33825600
4
Relationships of orientation discrimination threshold and visual acuity with macular lesions in age-related macular degeneration.
Fu H, Zhang B, Tong J, et al.
PloS one 2017; (12(9)):e0185070 doi:10.1371/journal.pone.0185070.
PMID: 28922378
5
Quality of life in patients with neovascular age-related macular degeneration before and after intravitreal therapy: a longitudinal observational study.
Nowak M, Cybulska AM, Derezińska A, et al.
Frontiers in medicine 2026; (13()):1731481 doi:10.3389/fmed.2026.1731481.
PMID: 42292229
6
Challenges Associated with Estimating Utility in Wet Age-Related Macular Degeneration: A Novel Regression Analysis to Capture the Bilateral Nature of the Disease.
Hodgson R, Reason T, Trueman D, et al.
Advances in therapy 2017; (34(10)):2360-2370 doi:10.1007/s12325-017-0620-x.
PMID: 29019023
7
Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration: Early Detection of Neovascular Age-Related Macular Degeneration Study.
Sivaprasad S, Banister K, Azuro-Blanco A, et al.
Ophthalmology 2021; (128(12)):1736-1747 doi:10.1016/j.ophtha.2021.07.025.
PMID: 34329651
8
Incidence of Macular Atrophy after Untreated Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study Report 40.
Christakis PG, Agrón E, Klein ML, et al.
Ophthalmology 2020; (127(6)):784-792 doi:10.1016/j.ophtha.2019.11.016.
PMID: 31899035
9
Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature.
Stanescu-Segall D, Balta F, Jackson TL
Survey of ophthalmology 2016; (61(1)):18-32.
PMID: 26212151
10
Recent Updates on the Diagnosis and Management of Age-Related Macular Degeneration.
Boopathiraj N, Wagner IV, Dorairaj SK, et al.
Mayo Clinic proceedings. Innovations, quality & outcomes 2024; (8(4)):364-374 doi:10.1016/j.mayocpiqo.2024.05.003.
PMID: 39036487
11
Latest Developments in Polypoidal Choroidal Vasculopathy: Epidemiology, Etiology, Diagnosis, and Treatment.
Chaikitmongkol V, Cheung CMG, Koizumi H, et al.
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; (9(3)):260-268 doi:10.1097/01.APO.0000656992.00746.48.
PMID: 32332215
12
Asian age-related macular degeneration: from basic science research perspective.
Yanagi Y, Foo VHX, Yoshida A
Eye (London, England) 2019; (33(1)):34-49 doi:10.1038/s41433-018-0225-x.
PMID: 30315261
13
Anti-Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy.
Kokame GT, deCarlo TE, Kaneko KN, et al.
Ophthalmology. Retina 2019; (3(9)):744-752 doi:10.1016/j.oret.2019.04.018.
PMID: 31511169
14
Variations in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy Phenotypes and Treatment Outcomes Across Singaporean, Canadian Asian, and Canadian Caucasian Populations.
Huang A, Ling J, Gilead N, et al.
American journal of ophthalmology 2026; (292()):163-174 doi:10.1016/j.ajo.2026.08.018.
PMID: 42600888
15
Polypoidal choroidal vasculopathy in Canada.
Lam WC, Choudhry N, Wong D
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2020; (55(3)):199-211 doi:10.1016/j.jcjo.2019.10.011.
PMID: 31879067
16
Macular neovascularization and polypoidal choroidal vasculopathy: phenotypic variations, pathogenic mechanisms and implications in management.
Cheung CMG
Eye (London, England) 2024; (38(4)):659-667 doi:10.1038/s41433-023-02764-w.
PMID: 37803144
17
Non-invasive testing for early detection of neovascular macular degeneration in unaffected second eyes of older adults: EDNA diagnostic accuracy study.
Banister K, Cook JA, Scotland G, et al.
Health technology assessment (Winchester, England) 2022; (26(8)):1-142 doi:10.3310/VLFL1739.
PMID: 35119357
18
Home-monitoring for neovascular age-related macular degeneration in older adults within the UK: the MONARCH diagnostic accuracy study.
Hogg RE, Wickens R, O'Connor S, et al.
Health technology assessment (Winchester, England) 2024; (28(32)):1-136 doi:10.3310/CYRA9912.
PMID: 39023220

This page about wet AMD symptoms and progression is for informational purposes only and does not constitute medical advice. Contact your ophthalmologist or retina specialist promptly about new vision changes or concerns.

Guide Contents